Assembly Biosciences Files Q3 2024 10-Q
Ticker: ASMB · Form: 10-Q · Filed: 2024-11-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
Related Tickers: ASMB
TL;DR
ASMB Q3 10-Q filed. Financials updated.
AI Summary
Assembly Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operations, including its cash and equivalents, and retained earnings. Specific financial figures and operational details are presented within the report.
Why It Matters
This filing provides investors and stakeholders with a crucial update on Assembly Biosciences' financial health and operational status for the third quarter of 2024.
Risk Assessment
Risk Level: medium — Biotech companies often carry inherent risks due to the nature of drug development and regulatory approvals.
Key Numbers
- 2023-12-31 — Previous Year End (Used for comparative financial analysis)
- 2022-12-31 — Prior Year End (Used for comparative financial analysis)
- 2023-01-01 to 2023-09-30 — Year-to-Date Period (Financial performance for the first nine months of 2023)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241107 (date) — Filing date
- 001-35005 (dollar_amount) — SEC file number
FAQ
What was Assembly Biosciences' cash and equivalents balance as of September 30, 2024?
The filing indicates figures related to cash equivalents and fair value measurements, but a specific total dollar amount for cash and equivalents as of September 30, 2024, is not explicitly stated in the provided snippet.
What is the company's retained earnings as of the latest reporting period?
The filing references 'us-gaap:RetainedEarningsMember' with a date of '2022-12-31', indicating retained earnings were reported as of the end of 2022.
When was the company formerly known as Ventrus Biosciences Inc.?
The company was formerly known as Ventrus Biosciences Inc. and the date of the name change was 20080211.
What is the SIC code for Assembly Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Assembly Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of Assembly Biosciences, Inc.?
The business address is Two Tower Place, 7th Floor, South San Francisco, CA 94080.
From the Filing
0000950170-24-123402.txt : 20241107 0000950170-24-123402.hdr.sgml : 20241107 20241107162408 ACCESSION NUMBER: 0000950170-24-123402 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 241436216 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 10-Q 1 asmb-20240930.htm 10-Q 10-Q --12-31 0001426800 false Q3 .1429 .0588 .0833 .0833 .0833 http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember http://fasb.org/us-gaap/2024#CashEquivalentsMember 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:RetainedEarningsMember 2022-12-31 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2020-08-31 0001426800 2023-01-01 2023-09-30 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:RetainedEarningsMember 2024-09-30 0001426800 srt:MaximumMember 2023-09-30 0001426800 2024-07-01 2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001426800 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 asmb:TwoThousandAndTwentyAtTheMarketOfferingsMember 2024-07-01 2024-09-30 0001426800 srt:MaximumMember 2023-07-01 2023-09-30 0001426800 asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001426800 us-gaap:CommonStockMember 2023-06-30 0001426800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001426800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001426800 2024-09-30 0001426800 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001426800 asmb:GileadSciencesIncorporatedMember srt:MaximumMember asmb:OptionLicenseAndCollaborationAgreementMember 2023-10-01 2023-10-31 0001426800 2022-12-31 0001426800 asmb:SecuritiesPurchaseAgreementMember 2024-06-01 2024-06-30 0001426800 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:FairValueInputsLevel3Member asmb:USAndForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 srt:MinimumMember 2024-01-01 2024-01-31 0001426800 us-gaap:WarrantMember srt:MaximumMember asmb:SecuritiesPurchaseAgreementMember 2024-06-01 2024-06-30 0001426800 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001426800 us-gaap:CommonStockMember 2023-09-30 0001426800 us-gaap:RetainedEarningsMember 2023-01-01 20